Filing Details

Accession Number:
0001209191-16-151526
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-11-21 21:10:30
Reporting Period:
2016-11-17
Filing Date:
2016-11-21
Accepted Time:
2016-11-21 21:10:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1088856 Corcept Therapeutics Inc CORT Pharmaceutical Preparations (2834) 770487658
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1419701 L.p. Partners Venture Longitude C/O Longitude Capital Partners, Llc
800 El Camino Real, Suite 220
Menlo Park CA 94025
No No Yes No
1430719 Longitude Capital Associates, L.p. 800 El Camino Real Suite 220
Menlo Park CA 94024
No No Yes No
1430720 Longitude Capital Partners, Llc 800 El Camino Real Suite 220
Menlo Park CA 94024
No No Yes No
1431159 Juliet Bakker Tammenoms 800 El Camino Real Suite 220
Menlo Park CA 94024
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-11-17 318,764 $9.64 14,026,757 No 4 S Direct
Common Stock Disposition 2016-11-17 6,389 $9.64 185,133 No 5 S Indirect By LCA
Common Stock Disposition 2016-11-18 98,586 $9.47 13,928,171 No 4 S Direct
Common Stock Disposition 2016-11-18 1,976 $9.47 183,157 No 4 S Indirect By LCA
Common Stock Disposition 2016-11-21 116,058 $9.39 13,812,113 No 4 S Direct
Common Stock Disposition 2016-11-21 2,327 $9.39 180,830 No 4 S Indirect By LCA
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 5 S Indirect By LCA
No 4 S Direct
No 4 S Indirect By LCA
No 4 S Direct
No 4 S Indirect By LCA
Footnotes
  1. Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5300 to $9.8000. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
  2. Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein.
  3. Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein.
  4. Reflects sales of common stock executed in multiple transactions at prices ranging from $9.4500 to $9.5400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
  5. Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3300 to $9.4800. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.